Evidence map›Paper›PMID 41589909›Full record

ArticleJournal of virology2026

MPXV RNA-seq data provide evidence for protection of viral transcripts from APOBEC3 editing.

Alisa O Lyskova, Ruslan Kh Abasov, Anna Pavlova, Evgenii V Matveev, Alexandra V Madorskaya, Fedor M Kazanov, Daria V Garshina, Anna E Smolnikova, Gennady V Ponomarev, Elena I Sharova and 4 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alisa O Lyskova *Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Ruslan Kh Abasov *Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Anna PavlovaDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Evgenii V MatveevDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.ORCID 0009-0008-2103-4978
Alexandra V MadorskayaNational Research University Higher School of Economics, Moscow, Russia.ORCID 0009-0008-0946-6890
Fedor M KazanovNational Research University Higher School of Economics, Moscow, Russia.
Daria V GarshinaLomonosov Moscow State University, Moscow, Russia.
Anna E SmolnikovaLomonosov Moscow State University, Moscow, Russia.
Gennady V PonomarevVavilov Institute of General Genetics, Moscow, Russia.ORCID 0000-0003-1271-9007
Elena I SharovaLopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.
Dmitry N IvankovCenter for Bio- and Medical Technologies, Moscow, Russia.ORCID 0000-0002-8224-4118
Ogun AdebaliSabanci University, Istanbul, Turkey.
Mikhail S GelfandCenter for Bio- and Medical Technologies, Moscow, Russia.ORCID 0000-0003-4181-0846
Marat D KazanovDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.ORCID 0000-0002-2314-5507

Funding

Assignment FFRW-2024-0004RSF 25-14-00491
6 · The paper itself

Abstract

The 2022 outbreak of monkeypox virus (MPXV), a double-stranded DNA virus, is remarkable for an unusually high number of single-nucleotide substitutions compared to earlier strains, with a strong bias toward C→T and G→A transitions consistent with the APOBEC3 cytidine deaminase activity. While APOBEC3-induced mutagenesis is well documented at the DNA level, its potential impact on MPXV RNA transcripts remains unclear. To assess whether APOBEC3 enzymes act on MPXV RNA, we analyzed RNA-seq data from infected samples. The enrichment of APOBEC signature substitutions among high-frequency mismatched positions led us to consider two possibilities: RNA editing at hotspots or fixed DNA mutations. Multiple lines of evidence support the conclusion that these substitutions arise from DNA-level mutagenesis rather than RNA editing. These include a substantial number of G→A substitutions remaining after normalization by gene strand direction, a largely neutral impact of substitutions on protein-coding sequences, the lack of positional correlation with transcriptional features or RNA secondary structure typically associated with APOBEC action hotspots, and an overlap with known genomic mutations in MPXV strains. Analysis of the nucleotide context of observed substitutions indicated that APOBEC3A or APOBEC3B was likely a driver of DNA-level mutagenesis.IMPORTANCEThe 2022 monkeypox virus (MPXV) outbreak showed an unusually high number of mutations thought to result from human antiviral enzymes of the APOBEC3 family. While such mutations have been clearly documented in the viral DNA, whether APOBEC3 also edits viral messenger RNA molecules remained unclear. In this study, we analyzed multiple publicly available MPXV RNA sequencing datasets to address this question. We found that the apparent APOBEC-like changes in RNA are best explained by fixed DNA mutations rather than active RNA editing. This finding helps clarify how MPXV evolves and adapts, suggesting that APOBEC3's role in shaping the virus likely operates at the DNA level. Understanding where and how these mutations occur provides insight into the virus's interaction with the human immune system and informs future studies on viral evolution and antiviral defenses.

Indexed as

Cytidine DeaminaseRNA EditingRNA, ViralAnimalsAPOBEC DeaminasesHumansMutagenesisMutationRNA-SeqAPOBEC3 proteins, humanAPOBEC DeaminasesCytidine DeaminaseRNA, ViralAPOBEChost–virus interactionsmonkeypoxmpoxMPXVmutagenesis

Identifiers

PMID41589909
PMCPMC12911903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.